ENG
R&D Pipeline and
Development Status
- Project Candidate
- Target Disease
- Discovery
- Preclinical
- IND
- Clinical
GIC-102
(T.O.P. NK®)
Solid / Hematologic cancers
- Description : NK cell therapy activated and amplified using ONLY the ancillary proteins. Without genetic modification or viral transduction, CD16 expression and cytotoxic granule contents are HIGHLY ELEVATED in T.O.P. NK cells.
- Technology : NKPURE Expander® Platform
GIC-201
(X-Pres T CELL®)
Solid cancers
- Description :Selectively educated CTLs through a process called “cross-presentation” and personalized antigen profiling to eliminate cancer cells expressing the target antigens.
- Technology : CTLPure ExpanderTM Platform
GIC-101
(Nano NK®)
Solid cancers
- Description : Allogeneic NK cell reinforced with chemo-loaded nanoparticles
- Technology : NKPURE Expander® Platform
GIC-302
(Drone Treg®)
Inflammatory Bowel Disease
- Description : Autologous regulatory T cell highly expressing organ specific homing receptors for the treatment of inflammatory disease
- Technology : TregPure ExpanderTM Platform
CAR NK
Solid/ Hematologic cancer
- Description :Allogeneic NK cell therapies with Chimeric Antigen Receptors(CAR)
- Technology : NKPURE Expander® Platform
- Partners : HK inno.N, Cartexell
